Replies to post #311814 on Avid Bioservices Inc (CDMO)

[biopharm]

Dr Crystal L Mackall must be listening to Dr Jedd Wolchok

With the recent radiation combined PS Targeting.....Dr Mackall has an interesting video here re: irradiation and immunotherapy

https://www.google.com/url?sa=t&source=web&rct=j&url=%23&ved=0ahUKEwjZhpXezLjWAhUL2oMKHRkcBMcQwqsBCIIBMBI&usg=AFQjCNF1sHlk2z9QIx28jtvfnGP_UlkifA

[biopharm]

“We have entered the golden age of immunotherapy for cancer,” Mackall said.

I have always said "The Enlightenment Age of Disease" is upon us right now ....eye of this storm continues as non-disclosed and NCCN MSK collaborations see the value in PS Targeting

Future cancer research priorities in the USA: a Lancet Oncology Commission
Prof Elizabeth M Jaffee, MD'Correspondence information about the author Prof Elizabeth M JaffeeEmail the author Prof Elizabeth M Jaffee, Prof Chi Van Dang, PhD'Correspondence information about the author Prof Chi Van DangEmail the author Prof Chi Van Dang, David B Agus, MD, Brian M Alexander, MD, Kenneth C Anderson, MD, Alan Ashworth, PhD, Anna D Barker, PhD, Roshan Bastani, PhD, Sangeeta Bhatia, MD, Jeffrey A Bluestone, PhD, Otis Brawley, MD, Atul J Butte, MD, Daniel G Coit, MD, Nancy E Davidson, MD, Mark Davis, PhD, Ronald A DePinho, MD, Robert B Diasio, MD, Giulio Draetta, MD, A Lindsay Frazier, MD, Andrew Futreal, PhD, Sam S Gambhir, PhD, Patricia A Ganz, MD, Levi Garraway, MD Phd, Stanton Gerson, MD, Sumit Gupta, PhD, James Heath, PhD, Ruth I Hoffman, MPH, Cliff Hudis, MD, Chanita Hughes-Halbert, PhD, Ramy Ibrahim, MD, Hossein Jadvar, MD Phd, Brian Kavanagh, MD, Rick Kittles, PhD, Quynh-Thu Le, MD, Scott M Lippman, MD, David Mankoff, MD PhD, Elaine R Mardis, PhD, Deborah K Mayer, PhD, Kelly McMasters, MD, Neal J Meropol, MD, Beverly Mitchell, MD, Peter Naredi, MD, Dean Ornish, MD, Timothy M Pawlik, MD, Jeffrey Peppercorn, MD, Martin G Pomper, MD PhD, Derek Raghavan, MD, Christine Ritchie, MD, Prof Sally W Schwarz, RPh, Richard Sullivan, MD, Richard Wahl, MD, Jedd D Wolchok, PhD, Sandra L Wong, MD, Alfred Yung, MD
..
.

Summary
We are in the midst of a technological revolution that is providing new insights into human biology and cancer. In this era of big data, we are amassing large amounts of information that is transforming how we approach cancer treatment and prevention. Enactment of the Cancer Moonshot within the 21st Century Cures Act in the USA arrived at a propitious moment in the advancement of knowledge, providing nearly US$2 billion of funding for cancer research and precision medicine. In 2016, the Blue Ribbon Panel (BRP) set out a roadmap of recommendations designed to exploit new advances in cancer diagnosis, prevention, and treatment. Those recommendations provided a high-level view of how to accelerate the conversion of new scientific discoveries into effective treatments and prevention for cancer. The US National Cancer Institute is already implementing some of those recommendations. As experts in the priority areas identified by the BRP, we bolster those recommendations to implement this important scientific roadmap. In this Commission, we examine the BRP recommendations in greater detail and expand the discussion to include additional priority areas, including surgical oncology, radiation oncology, imaging, health systems and health disparities, regulation and financing, population science, and oncopolicy. We prioritise areas of research in the USA that we believe would accelerate efforts to benefit patients with cancer. Finally, we hope the recommendations in this report will facilitate new international collaborations to further enhance global efforts in cancer control.

http://www.thelancet.com/pdfs/journals/lanonc/PIIS1470-2045(17)30698-8.pdf